Abstract:Introduction: Alzheimer's disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau antibodies are the most advanced therapeutic approach at present. Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in the coming months. In this systematic review, we review all Phase 2 and Phase 3 clinical trials conducted in this indication and the particularities of the molecules tested. Methods: The PubMed and ClinicalTrials.gov databases were searched through February 2023 for Phase 2 and 3 clinical trials involving passive anti-amyloid or anti-tau immunotherapies with published results. This review has been compiled in compliance with the PRISMA checklists. Results: Of the 165 studies found and after eliminating duplicates, 40 studies had their results published on PubMed and/or ClinicalTrials.gov. Eight anti-amyloid molecules and four anti-tau molecules were the subject of Phase 2 studies, seven anti-amyloids were the subject of Phase 3 trials, and two molecules were granted early marketing approval by the US Food and Drug Administration (FDA). The results were compiled in summary tables showing the primary endpoints used, results, age of the study population and specific adverse events for these molecules. Discussion: Passive immunotherapy in AD is largely dominated by anti-amyloid antibodies, which are more numerous and more advanced in the pipeline. Lecanemab, donanemab and aducanumab are distinguished by their relative efficacy in terms of cognitive and functional evaluation but also by a decrease in amyloid and tau proteins in the brain. These three molecules have in common that they bind to N-terminal ends of amyloid fibrils and plaques. The findings of their studies raise the question of which criteria to apply when choosing which patient will receive them when marketed, such as the apoliprotein E gene's fourth allele (APOE4) genetic status of patients. The large number of negative studies may also raise the question of the criteria for defining the disease and the possible interest in redefining it on biological grounds to offer a more personalized medicine to patients suffering from neurodegenerative diseases.

P143: New therapies for Alzheimer's dementia and its implications on healthcare system: are we ready?

Advances in Alzheimer's disease's pharmacological treatment

Alzheimer's disease and its treatment–yesterday, today, and tomorrow

[Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease]

Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease

Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies

Recent Advances in the Treatment and Management of Alzheimer’s Disease: A Precision Medicine Perspective

Recent Advances in Therapeutics for the Treatment of Alzheimer's Disease

Amyloid-Directed Antibodies: Past, Present, and Future

Advancements in Pharmacological Treatment of Alzheimer’s Disease: the Advent of Disease-Modifying Therapies (Dmts)

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges

Advancements in Pharmacological Treatment of Alzheimer's Disease: The Advent of Disease-Modifying Therapies (DMTs)

Current and Future Treatments in Alzheimer Disease: An Update

Therapeutics of Alzheimer's Disease: Recent Developments

Advances In Alzheimer'S Disease: A Multifaceted Review Of Potential Therapies And Diagnostic Techniques For Early Detection

Novel Therapeutic Strategies for Dementia

Treatment of Alzheimer's disease; current status and new perspectives

Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer's disease

New horizons in the diagnosis and management of Alzheimer’s Disease in older adults

Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks